Treace prelim Q1 rev $47.0-47.2M; FY26 guidance raised to $202-212M; CCO departs

TREACE MEDICAL CONCEPTS, INC.

2026-Q1 EPS reported -$0.28 revenue$47,198,000

Preliminary Q1 revenue expected $47.0-47.2M; cash $51.9M, up $3.5M from Dec 2025.
Full-year 2026 revenue guidance updated to $202-212M vs prior $200-212M.
Chief Commercial Officer Gaetano Guglielmino departed April 8; role not replaced.
CCO to consult through Jan 2027; $36,667/month fee, COBRA, prorated bonus, equity vest.
SVP Sales will now report directly to CEO John Treace.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.